Factorial Partners LLC Has $5.10 Million Position in Solventum Corporation (NYSE:SOLV)

Key Points

• Factorial Partners LLC has reduced its stake in Solventum Corporation (NYSE:SOLV) by 9.9%, now owning 67,000 shares valued at approximately $5.1 million.
• Several analysts have upgraded their ratings for Solventum, with Morgan Stanley and Piper Sandler changing their ratings to "overweight" and raising target prices significantly.
• Solventum reported better-than-expected quarterly earnings of $1.34 per share, exceeding analyst estimates of $1.19, along with a revenue of $2.07 billion.

Factorial Partners LLC reduced its stake in Solventum Corporation (NYSE:SOLV - Free Report) by 9.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,000 shares of the company's stock after selling 7,400 shares during the period. Solventum makes up 3.1% of Factorial Partners LLC's portfolio, making the stock its 7th biggest position. Factorial Partners LLC's holdings in Solventum were worth $5,095,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of SOLV. Clarity Asset Management Inc. purchased a new position in shares of Solventum during the fourth quarter valued at approximately $25,000. Rossby Financial LCC bought a new stake in shares of Solventum in the first quarter worth $25,000. Raiffeisen Bank International AG bought a new stake in shares of Solventum in the fourth quarter worth $29,000. Colonial Trust Co SC increased its position in Solventum by 240.7% during the fourth quarter. Colonial Trust Co SC now owns 511 shares of the company's stock valued at $34,000 after acquiring an additional 361 shares during the last quarter. Finally, Hara Capital LLC bought a new position in Solventum in the first quarter valued at about $38,000.

Solventum Price Performance

Shares of Solventum stock traded down $0.58 on Thursday, hitting $71.99. 1,313,737 shares of the company traded hands, compared to its average volume of 602,358. The company has a debt-to-equity ratio of 2.40, a quick ratio of 0.85 and a current ratio of 1.19. The stock has a market capitalization of $12.45 billion, a P/E ratio of 33.33, a price-to-earnings-growth ratio of 1.86 and a beta of 0.52. The business has a 50-day simple moving average of $74.20 and a 200 day simple moving average of $73.01. Solventum Corporation has a 52 week low of $55.62 and a 52 week high of $85.92.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, beating analysts' consensus estimates of $1.45 by $0.24. Solventum had a return on equity of 31.01% and a net margin of 4.55%. The business's quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.56 earnings per share. Research analysts expect that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Piper Sandler upgraded Solventum from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $78.00 to $87.00 in a research note on Monday, May 19th. KeyCorp started coverage on shares of Solventum in a research report on Friday, June 6th. They set a "sector weight" rating for the company. Argus upgraded shares of Solventum from a "hold" rating to a "buy" rating and set a $90.00 price target on the stock in a research note on Tuesday, July 1st. Finally, Morgan Stanley upgraded Solventum from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $80.00 to $103.00 in a research note on Tuesday, July 15th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $84.38.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.